Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03886077 Recruiting - Clinical trials for Coronary Artery Disease

Study of Hepatitis Eradication Receiving Protease Inhibitor Administration

SHERPA
Start date: March 20, 2019
Phase:
Study type: Observational

This is a prospective, non-blinded cohort study that will assess the safety, tolerability, and antiviral efficacy of glecaprevir/pibrentasivir therapy given post-discharge to HCV-negative recipients of HCV infected donors. Patients who meet entry criteria will be enrolled while on the transplant waitlist. At the time of transplant, some donors will be HCV positive / NAT positive and some will not be infected. Enrolled patients who receive an HCV negative donor will serve as contemporaneous controls. All study subjects who receive an HCV positive organ will be confirmed to have acquired HCV infection and genotype will be assessed prior to treatment with therapy.

NCT ID: NCT03878290 Recruiting - Obesity Clinical Trials

RiSE to Prevent Cardiovascular Disease in African Americans

Start date: August 3, 2017
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to evaluate an innovative 8-wk stress reduction program called Resilience, Stress and Ethnicity (RiSE) program designed to reduce chronic stress associated with perceived discrimination among African Americans. African Americans residing in the Maywood community between the ages of 25 and 75 with at least one cardiovascular disease risk factor such as being overweight, having high blood pressure, or diabetes will be enrolled. The following specific aims will be addressed: Aim 1: Determine the feasibility and acceptability of the program as a strategy to reduce chronic stress in African Americans within the Maywood and surrounding community. Aim 2: Examine the extent to which training in RiSE (1) improves psychological well being, (2) decreases inflammatory burden, and (3) reduces cardiovascular risk in African Americans Participants will be randomized to either the RiSE program or the control (no intervention group). Participants will provide blood and saliva samples as well as complete written questionnaires asking them questions about their health, well-being, and early life at the start of the study, half way through the study (at 4 weeks), at the completion of the intervention (8 weeks) and 3 months after the completion of the intervention).

NCT ID: NCT03877003 Recruiting - Clinical trials for Coronary Artery Disease

Plasma TMAO and Choline Levels in Individuals With Metabolic Syndrome - Comparison Between Eggs and Choline Supplement.

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The objective of this study is to determine the effects of consuming either 3 eggs per day and compare it to daily choline supplement (choline bitartrate) for a dose of approximately 400 mg/day on plasma concentrations of high density lipoprotein cholesterol (HDL-c), trimethylamine N oxide (TMAO) and plasma choline. The goal is to determine if choline given as phosphatidyl choline (from eggs) will have a more beneficial effect on plasma choline and microbiota.

NCT ID: NCT03874481 Recruiting - Clinical trials for Coronary Artery Disease

The Effect of Sleep Quality on Coronary Artery Disease and In Stent Restenosis

Start date: November 1, 2018
Phase:
Study type: Observational

This is a cross-sectional and follow-up study. We analysis the relationship of sleep quality on coronary artery disease(CAD) and in stent restenosis(ISR). Further, we explore the mechanism of relationship between the sleep quality and CAD/ ISR by examining the biomarkers in the pathway of sleep-CAD/ISR.

NCT ID: NCT03870815 Recruiting - Clinical trials for Ischemic Heart Disease

Long-term Outcomes and Prognostic Factors in Patient Undergoing Coronary Artery Bypass Graft Surgery or Percutaneous Coronary Intervention

Start date: February 27, 2019
Phase:
Study type: Observational

1. To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary artery disease undergoing coronary artery bypass graft surgery. 2. To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary artery disease undergoing percutaneous coronary intervention with second generation drug-eluting stent.

NCT ID: NCT03859102 Recruiting - Clinical trials for Coronary Artery Disease

Enhanced Recovery After Cardiac Surgery

ERAS
Start date: December 17, 2018
Phase: N/A
Study type: Interventional

Enhanced Recovery Protocols (ERPs or bundles) have been established in many surgical specialties (such as colon cancer and orthopaedic joint surgeries) for several years in hospitals worldwide. The principles of Enhanced Recovery Protocols are those of early mobilization and restoration of normal function as soon as possible after surgery. These principles are achieved by use of alternate pain control regimens and removing invasive lines and drains as soon as possible. The benefits of ERPs are improved patient experience, earlier return to normal function and reduced length of stay. Enhanced recovery protocols for cardiac surgery have been published by the Enhanced Recovery After Cardiac Surgery Society. The current study will investigate whether it is possible to utilise ERP bundles in the population of cardiac surgery patients at James Cook Hospital, with a view to rolling out a full ERP service. Secondary study outcomes will be patient-centred, including; pain scores, nausea and vomiting rates and time taken to return to normal function.

NCT ID: NCT03857971 Recruiting - Clinical trials for Coronary Artery Disease

Identification of Risk Factors for Acute Coronary Events by Optical Coherence Tomography After STEMI and NSTEMI in Patients With Residual Non-flow Limiting Lesions

PECTUS-obs
Start date: December 14, 2018
Phase: N/A
Study type: Interventional

The objective of this study is to compare the clinical outcome of NSTEMI and STEMI patients with non-obstructive, non-culprit coronary lesions and either presence or absence of vulnerable plaque characteristics as assessed by OCT.

NCT ID: NCT03857711 Recruiting - Clinical trials for Cardiovascular Diseases

Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation)

PULVAB
Start date: September 1, 2016
Phase: N/A
Study type: Interventional

To compare prophylactic strategies of atrial fibrillation in patients with CAD and without AF.

NCT ID: NCT03855891 Recruiting - Atherosclerosis Clinical Trials

Evaluation of the Circulating Micro-RNA Profile Specificity in Patients With Different Stages of Atherosclerosis According to MSCT Coronary Angiography

CT-CA-miRNA
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The main purpose of this single-center study is to determine the spectrum and levels of cardiospecific circulating microRNAs in patients with different stages of atherosclerosis according to 640-slice multispiral computed tomography (MSCT).

NCT ID: NCT03855436 Recruiting - Clinical trials for Coronary Angiography

Risk Factors of Intermediate Coronary Lesion Progression

Start date: January 2017
Phase:
Study type: Observational

Coronary intermediate lesions generally refer to lumen narrowing with diameter stenosis% (DS%) between 50% and 70% on angiography. Prognosis varies significantly among patients with intermediate lesions, and some lesions progress rapidly leading to adverse cardiovascular events. Therefore, accurate risk stratification is important and will help clinicians identify patients at high risk of adverse events. The aim of study is to identify independent risk factors for major adverse cardiovascular events (MACE) among patients with intermediate lesions. The study is a prospective, single-center, ongoing, observational study, which aims at enrolling approximately 1389 patients with intermediate coronary lesions. After enrollment, the following data are collected for each participant: baseline characteristics including demographics, clinical presentation, traditional risk factor, diagnosis and management; lesion characteristics assessed by coronary angiography; quantitative flow reserve; lab tests including blood chemistry, blood lipid, hemoglobin A1C, cardiac biomarker, BNP, et al. Patients are followed up at 2 year for primary outcome including death, myocardial infarction and repeat unplanned revascularization. A risk prediction score will be established and validated for major adverse cardiovascular disease at two-year follow-up.